Leap Therapeutics Inc
NASDAQ:LPTX
Leap Therapeutics Inc
NASDAQ:LPTX
Price:
2.38 USD
-3.64%
Market Closed
Updated:
May 28, 2024
Leap Therapeutics Inc
Interest Income Expense
|
Leap Therapeutics Inc
Interest Income Expense Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Leap Therapeutics Inc
NASDAQ:LPTX
|
Interest Income Expense
$4.2m
|
CAGR 3-Years
35%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Interest Income Expense
-$1.8B
|
CAGR 3-Years
11%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Income Expense
-$663m
|
CAGR 3-Years
38%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-8%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Income Expense
-$2.9B
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-16%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Income Expense
$630.1m
|
CAGR 3-Years
93%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Income Expense
$221.8m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
75%
|
CAGR 10-Years
N/A
|
See Also
What is Leap Therapeutics Inc's Interest Income Expense?
Interest Income Expense
4.2m
USD
4.2m
USD
Based on the financial report for Mar 31, 2024, Leap Therapeutics Inc's Interest Income Expense amounts to 4.2m USD.
What is Leap Therapeutics Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
-19%
-19%
Over the last year, the Interest Income Expense growth was 565%. The average annual Interest Income Expense growth rates for Leap Therapeutics Inc have been 35% over the past three years , -19% over the past five years .
You don't have any saved screeners yet
